Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Vaccine

• Publication date

  2017-01-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2016.09.045PMID 27692522PMCID PMC5189713
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses

  2016cited by this paper
• Erratum: Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation

  2016cited by this paper
• Taxonomy of the order Mononegavirales: update 2016

  2016cited by this paper
• Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.

  2015cited by this paper
• Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures

  2015cited by this paper
• Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein

  2015cited by this paper
• Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

  2015cited by this paper
• CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner

  2015cited by this paper
• Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein

  2015cited by this paper
• Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate

  2015cited by this paper
• A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

  2015cited by this paper
• CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

  2015cited by this paper
• Murine Immune Responses to Virus-Like Particle-Associated Pre- and Postfusion Forms of the Respiratory Syncytial Virus F Protein

  2015cited by this paper
• Proof of principle for epitope-focused vaccine design

  2014cited by this paper
• A Monomeric Uncleaved Respiratory Syncytial Virus F Antigen Retains Prefusion-Specific Neutralizing Epitopes

  2014cited by this paper
• Structural Insights into the Human Metapneumovirus Glycoprotein Ectodomain

  2014influential reference
• Broadly Neutralizing Human Monoclonal Antibody Exhibits In Vivo Ef fi cacy Against Both Human Metapneumovirus and Respiratory Syncytial Virus

  2014cited by this paper
• Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease

  2013cited by this paper
• Challenges and Opportunities for Respiratory Syncytial Virus Vaccines

  2013cited by this paper
• A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab′)2 Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice

  2013cited by this paper
• Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

  2013cited by this paper
• Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

  2013influential reference
• Circulation of HRSV in Belgium: From Multiple Genotype Circulation to Prolonged Circulation of Predominant Genotypes

  2013cited by this paper
• Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

  2013cited by this paper
• Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

  2013influential reference
• Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats

  2012cited by this paper
• Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein

  2012cited by this paper
• Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

  2012cited by this paper
• Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

  2012cited by this paper
• The Small Hydrophobic Protein of the Human Respiratory Syncytial Virus Forms Pentameric Ion Channels*

  2012cited by this paper
• Identification of nucleolin as a cellular receptor for human respiratory syncytial virus

  2011cited by this paper
• Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

  2011cited by this paper
• Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

  2011cited by this paper
• Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.

  2011cited by this paper
• Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

  2011cited by this paper
• Recombinant Sendai Viruses Expressing Fusion Proteins with Two Furin Cleavage Sites Mimic the Syncytial and Receptor-Independent Infection Properties of Respiratory Syncytial Virus

  2011cited by this paper
• Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion Glycoprotein

  2010cited by this paper
• Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naïve and Formalin-Inactivated RSV-Immunized BALB/c Mice

  2010cited by this paper
• Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

  2010cited by this paper
• Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice

  2009cited by this paper
• Respiratory Syncytial Virus Grown in Vero Cells Contains a Truncated Attachment Protein That Alters Its Infectivity and Dependence on Glycosaminoglycans

  2009cited by this paper
• Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming

  2009cited by this paper
• The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing Leukocytes

  2008cited by this paper
• Insertion of the Two Cleavage Sites of the Respiratory Syncytial Virus Fusion Protein in Sendai Virus Fusion Protein Leads to Enhanced Cell-Cell Fusion and a Decreased Dependency on the HN Attachment Protein for Activity

  2008cited by this paper
• Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity.

  2006cited by this paper
• Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation

  2006influential reference
• Identification of Linear Heparin-Binding Peptides Derived from Human Respiratory Syncytial Virus Fusion Glycoprotein That Inhibit Infectivity

  2006cited by this paper
• Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein.

  2005cited by this paper
• Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation

  2005cited by this paper
• Antigenic and Genetic Variability of Human Metapneumoviruses

  2004cited by this paper
• The Soluble Form of Human Respiratory Syncytial Virus Attachment Protein Differs from the Membrane-Bound Form in Its Oligomeric State but Is Still Capable of Binding to Cell Surface Proteoglycans

  2004cited by this paper
• Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

  2002cited by this paper
• Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.

  2002cited by this paper
• Effect of proteolytic processing at two distinct sites on shape and aggregation of an anchorless fusion protein of human respiratory syncytial virus and fate of the intervening segment.

  2002cited by this paper
• Analysis of the genomic sequence of a human metapneumovirus.

  2002cited by this paper
• Molecular epidemiology of respiratory syncytial virus

  2001cited by this paper
• CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein

  2001cited by this paper
• Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion

  2001cited by this paper
• Molecular epidemiology of respiratory syncytial virus.

  2001cited by this paper
• Functional Analysis of Recombinant Respiratory Syncytial Virus Deletion Mutants Lacking the Small Hydrophobic and/or Attachment Glycoprotein Gene

  2001cited by this paper
• Glycosaminoglycan Sulfation Requirements for Respiratory Syncytial Virus Infection

  2000cited by this paper
• The C-terminal third of human respiratory syncytial virus attachment (G) protein is partially resistant to protease digestion and is glycosylated in a cell-type-specific manner.

  2000cited by this paper
• Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

  2000cited by this paper
• Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans.

  2000cited by this paper
• Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies.

  2000cited by this paper
• Identification of a Linear Heparin Binding Domain for Human Respiratory Syncytial Virus Attachment Glycoprotein G

  1999cited by this paper
• Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein.

  1998cited by this paper
• Antigenic Structure of Human Respiratory Syncytial Virus Fusion Glycoprotein

  1998cited by this paper
• Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults.

  1998cited by this paper
• Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor.

  1998cited by this paper
• Identification of a conserved neutralization site in the first heptad repeat of the fusion protein of respiratory syncytial virus

  1998cited by this paper
• NetOglyc: Prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility

  1998cited by this paper
• Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.

  1997cited by this paper
• Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.

  1997cited by this paper
• Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants.

  1997cited by this paper
• Membrane permeability changes induced in Escherichia coli by the SH protein of human respiratory syncytial virus.

  1997cited by this paper
• Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus.

  1996cited by this paper
• Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein.

  1996cited by this paper
• The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons

  1994cited by this paper
• Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.

  1993cited by this paper
• Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A.

  1992cited by this paper
• Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

  1992cited by this paper
• Immunity to and frequency of reinfection with respiratory syncytial virus.

  1991cited by this paper
• Why are proteins O-glycosylated?

  1990cited by this paper
• Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins.

  1989cited by this paper
• Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

  1989cited by this paper
• Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins

  1989cited by this paper
• Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus.

  1988cited by this paper
• Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies

  1988cited by this paper
• The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.

  1987cited by this paper
• Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus.

  1987cited by this paper
• Risk of primary infection and reinfection with respiratory syncytial virus.

  1986cited by this paper
• Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein.

  1985cited by this paper
• Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies.

  1985cited by this paper
• Two distinct subtypes of human respiratory syncytial virus.

  1985cited by this paper
• Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein

  1983cited by this paper

• Broad-Spectrum Virucidal Activity of Nitric Oxide Nasal Spray (NONS) Against SARS-CoV-2 Variants and Major Respiratory Viruses

  2026cites this paper
• Respiratory Syncytial Virus Under the Lens of Structure: From Prefusion Stabilization to Next‐Generation Immunotherapies

  2026cites this paper
• Molecular Virology, Pathogenesis, and Clinical Management of Human Metapneumovirus

  2025cites this paper
• Stabilized Full-Length Measles Fusion Protein Elicits Potent Immunity and Protection In Vivo

  2025cites this paper
• A comparative review on the epidemiology of influenza, COVID-19 and respiratory syncytial viruses

  2025cites this paper
• Host Immune Response to Respiratory Syncytial Virus Infection in Children

  2025cites this paper
• RSV-Induced Epigenetic Reprogramming: Mechanisms and Therapeutic Opportunities

  2025cites this paper
• Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control.

  2025cites this paper
• Molecular characterization of human respiratory syncytial virus in Mexico (season 2023–2024) through whole-genome sequencing

  2025cites this paper
• Vaccine Development for Human Pneumoviruses

  2025cites this paper
• Host immune response to respiratory syncytial virus infection and its contribution to protection and susceptibility in adults: a systematic literature review

  2025cites this paper
• Review of impaired immune parameters in RSV infections in the elderly.

  2025cites this paper
• Interleukin-8 rs2227543 gene polymorphism in Egyptian infants with acute bronchiolitis

  2024cites this paper
• Evaluating the Impact of N-Glycan Sequon Removal in the p27 Peptide on RSV F Protein Immunogenicity and Functionality

  2024cites this paper
• Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue

  2024cites this paper
• Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus

  2024cites this paper
• Landscape of respiratory syncytial virus

  2024cites this paper
• Computational Insights into the Interaction of the Conserved Cysteine-Noose Domain of the Human Respiratory Syncytial Virus G Protein with the Canonical Fractalkine Binding site of Transmembrane Receptor CX3CR1 Isoforms

  2024cites this paper
• A tale of two fusion proteins: understanding the metastability of human respiratory syncytial virus and metapneumovirus and implications for rational design of uncleaved prefusion-closed trimers

  2024cites this paper
• All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?

  2024influential citation
• Influence of Sex on Respiratory Syncytial Virus Genotype Infection Frequency and Nasopharyngeal Microbiome

  2023cites this paper
• The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent

  2023cites this paper
• New Insights on Respiratory Syncytial Virus Prevention

  2023cites this paper
• Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies

  2023cites this paper
• Reshaping Our Knowledge: Advancements in Understanding the Immune Response to Human Respiratory Syncytial Virus

  2023cites this paper
• Genomic characterization of respiratory syncytial virus genotypes circulating in the paediatric population of Sydney, NSW, Australia

  2023cites this paper
• Preventative therapies for respiratory Syncytial virus (RSV) in children: Where are we now?

  2023cites this paper
• Mutation in the CX3C Motif of G Protein Disrupts Its Interaction with Heparan Sulfate: A Calorimetric, Spectroscopic, and Molecular Docking Study

  2022cites this paper
• ON-1 and BA-IX Are the Dominant Sub-Genotypes of Human Orthopneumovirus A&B in Riyadh, Saudi Arabia

  2022cites this paper
• Adult Memory T Cell Responses to the Respiratory Syncytial Virus Fusion Protein During a Single RSV Season (2018–2019)

  2022cites this paper
• Impact of genetic polymorphisms related to innate immune response on respiratory syncytial virus infection in children

  2022cites this paper
• Analysis of circulating respiratory syncytial virus A strains in Shanghai, China identified a new and increasingly prevalent lineage within the dominant ON1 genotype

  2022cites this paper
• Identification of antigenic epitopes on the F and G glycoproteins of bovine respiratory syncytial virus and in vitro assessment of their synthetic peptide vaccine potential

  2021cites this paper
• Respiratory Syncytial Virus G Protein Sequence Variability among Isolates from St. Petersburg, Russia, during the 2013–2014 Epidemic Season

  2021cites this paper
• Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine

  2021cites this paper
• The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines

  2021cites this paper
• Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?

  2021cites this paper
• Recommendations for respiratory syncytial virus surveillance at the national level

  2021cites this paper
• Roles of Human Respiratory Syncytial Virus Proteins in Immune Responses

  2021cites this paper
• Functional Features of the Respiratory Syncytial Virus G Protein

  2021cites this paper
• Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.

  2021cites this paper
• Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients

  2020cites this paper
• Emerging small and large molecule therapeutics for respiratory syncytial virus

  2020cites this paper
• Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

  2020influential citation
• Genetic characterization of G protein in respiratory syncytial virus ON-1 genotype in Tehran

  2020cites this paper
• Evolution of respiratory syncytial virus genotype BA in Kilifi, Kenya, 15 years on

  2020cites this paper
• Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines

  2020cites this paper
• Role of Respiratory Syncytial Virus in Pediatric Pneumonia

  2020cites this paper
• Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.

  2019cites this paper
• Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly

  2019cites this paper
• Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development

  2019cites this paper
• Genotyping of Type A Human Respiratory Syncytial Virus Based on Direct F Gene Sequencing

  2019cites this paper
• A Contemporary View of Respiratory Syncytial Virus (RSV) Biology and Strain-Specific Differences

  2019cites this paper
• Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon

  2019cites this paper
• Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study

  2019cites this paper
• Respiratory syncytial, parainfluenza and influenza virus infection in young children with acute lower respiratory infection in rural Gambia

  2019cites this paper
• Antibody Epitopes of Pneumovirus Fusion Proteins

  2019cites this paper
• Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein

  2019cites this paper
• Vaccines against human respiratory syncytial virus in clinical trials, where are we now?

  2019cites this paper
• Genetic characterization of respiratory syncytial virus highlights a new BA genotype and emergence of the ON1 genotype in Lyon, France, between 2010 and 2014.

  2018cites this paper
• EFFECTS OF VACCINE PLATFORMS AND ADJUVANTS ON PROTECTIVE EFFICACY AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS

  2018influential citation
• Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant

  2018cites this paper
• The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography

  2018cites this paper
• Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field

  2018cites this paper
• Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies

  2018cites this paper
• Novel immunological insights in accelerating RSV vaccine development.

  2017cites this paper
• Respiratory syncytial virus genotypes NA1, ON1, and BA9 are prevalent in Thailand, 2012–2015

  2017cites this paper
• Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

  2017cites this paper
• RSV Takes Control of Neonatal Breg Cells: Two Hands on the Wheel.

  2017cites this paper
• Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein

  2017cites this paper
• An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

  2017cites this paper
• Modi fi ed mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

  year unknowncites this paper